Malignancies in the ustekinumab psoriasis clinical development program: Final report with up to 5 years of follow-up

被引：0
|
作者：
Papp, Kim [1 ]
Gordon, Kenneth [2 ]
Szapary, Philippe [3 ]
Ho, Vincent [4 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Northwestern Univ, Feinberg Sch Med, Skokie, IL USA
[3] Janssen Res & Dev LLC, Spring House, PA USA
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2013年 / 68卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB206 / AB206
页数：1
相关论文
共 50 条
  • [1] Malignancies in the ustekinumab psoriasis clinical development programme: final report with up to 5 years of follow-up
    Papp, K.
    Gordon, K.
    Ho, V.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 40 - 40
  • [2] Infections in the ustekinumab psoriasis clinical trial program: Final report with up to 5 years of follow-up
    Strober, Bruce
    Lebwohl, Mark
    Ghislain, P. D.
    Szapary, Philippe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB203 - AB203
  • [3] Infections in the ustekinumab psoriasis clinical trial programme: final report with up to 5 years of follow-up
    Strober, B.
    Ghislain, P. D.
    Lebwohl, M.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 38 - 38
  • [4] Cardiovascular safety in the ustekinumab clinical development program: Final update with up to 5 years of follow-up
    Reich, Kristian
    Griffiths, C. E. M.
    Lebwohl, Mark
    Szapary, Philippe
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB194 - AB194
  • [5] Cardiovascular safety in the ustekinumab Clinical Development Programme: final update with up to 5 years of follow-up
    Reich, K.
    Lebwohl, M.
    Griffiths, C. E. M.
    Szapary, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 55 - 55
  • [6] Infection rates in the ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Menter, A.
    Reich, K.
    Szapary, P. O.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [7] Infection rates in the Ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Bissonnette, R.
    Leonardi, C.
    Menter, A.
    Szapary, P. O.
    Wasfi, Y.
    Ott, E.
    Hsu, M.
    van de Kerkhof, P.
    Reich, K.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 : 52 - 52
  • [8] An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
    Reich, Kristian
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Szapary, Philippe O.
    Yeilding, Newman
    Wasfi, Yasmine
    Ott, Elyssa
    Hsu, Ming-Chun
    Lebwohl, Mark
    Gordon, Kenneth B.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (03) : 300 - 312
  • [9] Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
    Papp, Kim
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Lebwohl, Mark
    Szapary, Philippe O.
    Wasfi, Yasmine
    Chan, Daphne
    Shen, Yaung-Kaung
    Ho, Vincent
    Ghislain, Pierre-Dominique
    Strober, Bruce
    Reich, Kristian
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S139 - S140
  • [10] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, K.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    [J]. SWISS MEDICAL WEEKLY, 2014, 144 : 5S - 5S
12345